BioGenes and FyoniBio combine scientific expertise, offer single source for pharmacokinetic and immunogenicity analyses
Pharmacokinetic and immunogenicity projects can be both diverse and complex, involving work packages from antibody generation and production to the analysis of clinical samples with validated assays.
In an effort to simplify the process, BioGenes and FyoniBio has signed an agreement under wich they will cooperate to provide a single source for these services.
BioGenes, as an expert in antibody production and ELISA setup, takes care of the first steps of the project, while FyoniBio, a specialist in bioassay development and validation for analysis of clinical samples, uses their expertise to transfer the assay to the MSD2 platform for analysing clinical samples under “good clinical and laboratory practice” (GCLP). Specialists at the Berlin-based companies guarantee comprehensive project management.
“We are very pleased that the cooperation with FyoniBio has now officially started,” said Dr. Alexander Knoll, CEO of BioGenes GmbH. “We are convinced that our complete package for high-quality and customized immunological tests for new biological compounds and clinical samples offers an enormous added value for customers.”
“Both companies want to provide the perfect service for each customer. In this respect, as well as regarding scientific excellence in their respective fields, the two companies complement each other very well,” added Dr. Hans Baumeister, Service Division Manager at FyoniBio. “We are looking forward to the first joint projects.”
